Golden
Inoviv

Inoviv

Inoviv develops proteomics-based biomarker tests to support pharmaceutical companies in running clinical trials.

All edits

Edits on 13 Aug 2019
Golden AI"IBI-79"
Golden AI edited on 13 Aug 2019 7:48 pm
Edits made to:
Infobox (+3 properties)

Infobox

Accelerator Batch
Company legal name
EM Scientific Limited (Inoviv)
Founded date
March 21, 2018
Edits on 17 Apr 2019
Dawson Sewell
Dawson Sewell edited on 17 Apr 2019 6:45 pm
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 11 Apr 2019
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 11 Apr 2019 7:14 pm
Edits made to:
Infobox (+1 properties)

Infobox

Meredith Hanel
Meredith Hanel edited on 11 Apr 2019 1:42 pm
Edits made to:
Infobox (+1 properties)
Article

Article

Inoviv’s services include Patient Identification and Stratification, Companion Diagnostics and Treatment Efficacy Monitoring. The company measures more than 50 calibrating molecules per biofluid sample and analyzes 3000 biofluid/tissue samples per day. Their technology uses mass spectrometry-based targeted proteomics to test multiplexed protein, peptide, lipid and metabolite biomarker panels. Mass spectrometry measures the mass-to-charge ratio of molecules. Inoviv’s uses a triple quadrupole mass spectrometry system. 

Infobox

Edits on 30 Mar 2019
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 30 Mar 2019 1:11 am
Edits made to:
Article (+17/-17 characters)

Article

Inoviv’s services include Patient Identification and Stratification, Companion Diagnostics and Treatment Efficacy Monitoring. The company measures more than 50 calibrating molecules per biofluid sample and analyzes 3000 biofluid/tissue samples per day. Their technology uses mass spectrometry-based targeted proteomics to test multiplexed protein, peptide, lipid and metabolite biomarker panels. Mass spectrometryMass spectrometry measures the mass-to-charge ratio of molecules. Inoviv’s uses a triple quadrupole mass spectrometry system. 

Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 29 Mar 2019 10:33 pm
Edits made to:
Article (+18/-18 characters)

Article

Inoviv pitched at Entrepreneur FirstEntrepreneur First’s 9th demo day in 2018.

Meredith Hanel
Meredith Hanel edited on 29 Mar 2019 8:09 pm
Edits made to:
Infobox (+7 properties)
Description (+113 characters)
Article (+944 characters)
People (+2 rows) (+4 cells) (+56 characters)
Further reading (+1 rows) (+4 cells) (+256 characters)
Categories (+1 topics)
Topic thumbnail

Inoviv

Inoviv develops proteomics-based biomarker tests to support pharmaceutical companies in running clinical trials.

Article

Inoviv’s technology is based on using proteomics, the large-scale study of proteins in an individual, to match patients with drugs. The company is developing biomarker tests which can identify patients most likely to respond to the drug. Biomarker endpoints are also designed to demonstrate efficacy of treatment on an ongoing basis during the clinical trial. 



Inoviv’s services include Patient Identification and Stratification, Companion Diagnostics and Treatment Efficacy Monitoring. The company measures more than 50 calibrating molecules per biofluid sample and analyzes 3000 biofluid/tissue samples per day. Their technology uses mass spectrometry-based targeted proteomics to test multiplexed protein, peptide, lipid and metabolite biomarker panels. Mass spectrometry measures the mass-to-charge ratio of molecules. Inoviv’s uses a triple quadrupole mass spectrometry system. 



Inoviv pitched at Entrepreneur First’s 9th demo day in 2018.

People

Name
Role
Related Golden topics

Ernestas Sirka

Co-Founder, CSO



Michael Dove

Co-Founder, CEO



Further reading

Title
Author
Link
Type

As the triple quadrupole turns 40, mass spec gurus look back on what it's meant to chemistry | March 5, 2018 Issue - Vol. 96 Issue 10 | Chemical & Engineering News

Celia Henry Arnaud

Web

Infobox

Categories

Meredith Hanel"Initial topic creation"
Meredith Hanel created this topic on 29 Mar 2019 7:24 pm
Edits made to:
Topic thumbnail

 Inoviv

Inoviv develops proteomics-based biomarker tests to support pharmaceutical companies in running clinical trials.

No more activity to show.